文献速递病毒性肝炎

乙型肝炎核心相关抗原:非洲评估治疗资格时HBV DNA的替代指标

Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa.
PubMed 文献 · Clin Infect Dis · 2020-01-01

研究在冈比亚284例未治疗慢性HBV感染者中评估血清HBcrAg替代HBV DNA判断治疗资格的性能。简化治疗算法AUROC为0.91,灵敏度96.6%,特异度85.8%。HBcrAg可能是中低收入国家筛选需抗病毒治疗者的准确、简便且廉价的替代工具。

要点

  • HBcrAg诊断HBV DNA≥2000 IU/mL的AUROC为0.88,灵敏度83.3%,特异度83.9%。
  • 不含HBV DNA的简化HBcrAg治疗算法灵敏度96.6%,特异度85.8%。

核心结论

  • HBcrAg可能是中低收入国家识别需抗病毒治疗HBV感染者的准确、简便且廉价的HBV DNA替代工具。

研究设计与样本

  • 在冈比亚一个特征明确的未治疗慢性HBV感染队列中评估血清HBcrAg诊断HBV DNA水平及判断治疗资格的准确性,共纳入284例未治疗患者。

关键数值与推荐

  • 治疗资格依据美国肝病研究学会标准,基于HBV DNA、HBeAg、ALT、肝组织病理学和/或FibroScan等参考检测判定。

临床怎么用

  • 在资源有限地区,可考虑用HBcrAg替代HBV DNA量化来筛选需抗病毒治疗的慢性HBV感染者。
  • HBcrAg检测费用低于15美元/次,可能有助于扩大HBV检测和治疗覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To eliminate hepatitis B virus (HBV) infection, it is essential to scale up testing and treatment. However, conventional tools to assess treatment eligibility, particularly nucleic acid testing (NAT) to quantify HBV DNA, are hardly available and affordable in resource-limited countries. We therefore assessed the performance of a novel immunoassay, hepatitis B core-related antigen (HBcrAg), as an inexpensive (US$ <15/assay) alternative to NAT to diagnose clinically important HBV DNA thresholds (≥2000, ≥20 000, and ≥200 000 IU/mL) and to select patients for antiviral therapy in Africa. METHODS: Using a well-characterized cohort of treatment-naive patients with chronic HBV infection in The Gambia, we evaluated the accuracy of serum HBcrAg to diagnose HBV DNA levels and to indicate treatment eligibility determined by the American Association for the Study of Liver Diseases, based on reference tests (HBV DNA, hepatitis B e antigen, alanine aminotransferase, liver histopathology, and/or FibroScan). RESULTS: A total of 284 treatment-naive patients were included in the analysis. The area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity of serum HBcrAg were 0.88 (95% confidence interval [CI], .82-.93), 83.3%, and 83.9%, respectively, to diagnose HBV DNA ≥2000 IU/mL; and 0.94 (95% CI, .88-.99), 91.4%, and 93.2% for ≥200 000 IU/mL. A simplified treatment algorithm using HBcrAg without HBV DNA showed high AUROC (0.91 [95% CI, .88-.95]) with a sensitivity of 96.6% and specificity of 85.8%. CONCLUSIONS: HBcrAg might be an accurate alternative to HBV DNA quantification as a simple and inexpensive tool to identify HBV-infected patients in need of antiviral therapy in low- and middle-income countries.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shimakawa Y, Ndow G, Njie R, et al. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis. 2020. PMID: 31102406. doi:10.1093/cid/ciz412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。